Enovis Corporation Logo

Enovis Corporation

ENOV

(1.2)
Stock Price

45,02 USD

-7.11% ROA

-0.95% ROE

-35.55x PER

Market Cap.

3.221.597.841,00 USD

13.52% DER

0% Yield

-1.92% NPM

Enovis Corporation Stock Analysis

Enovis Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Enovis Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.82x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (14%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

Negative ROE (-4.47%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-11.83%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-866), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Enovis Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Enovis Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Enovis Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Enovis Corporation Revenue
Year Revenue Growth
2004 309.653.000
2005 345.478.000 10.37%
2006 393.604.000 12.23%
2007 506.305.000 22.26%
2008 604.854.000 16.29%
2009 525.024.000 -15.21%
2010 541.987.000 3.13%
2011 693.392.000 21.84%
2012 3.913.856.000 82.28%
2013 4.207.209.000 6.97%
2014 4.624.476.000 9.02%
2015 3.967.053.000 -16.57%
2016 3.647.047.000 -8.77%
2017 3.300.184.000 -10.51%
2018 3.666.812.000 10%
2019 3.327.458.000 -10.2%
2020 3.070.769.000 -8.36%
2021 3.854.303.000 20.33%
2022 1.563.101.000 -146.58%
2023 1.670.096.000 6.41%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Enovis Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2004 3.175.000
2005 2.855.000 -11.21%
2006 3.336.000 14.42%
2007 4.162.000 19.85%
2008 5.856.000 28.93%
2009 5.930.000 1.25%
2010 6.205.000 4.43%
2011 5.707.000 -8.73%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 60.827.000 100%
2023 79.604.000 23.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Enovis Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Enovis Corporation EBITDA
Year EBITDA Growth
2004 1.725.000
2005 40.478.000 95.74%
2006 32.679.000 -23.87%
2007 89.812.000 63.61%
2008 31.477.000 -185.33%
2009 83.450.000 62.28%
2010 81.907.000 -1.88%
2011 89.575.000 8.56%
2012 256.673.000 65.1%
2013 564.486.000 54.53%
2014 642.398.000 12.13%
2015 500.364.000 -28.39%
2016 455.443.000 -9.86%
2017 384.956.000 -18.31%
2018 456.545.000 15.68%
2019 471.317.000 3.13%
2020 446.933.000 -5.46%
2021 558.409.000 19.96%
2022 131.140.000 -325.81%
2023 -81.968.000 259.99%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Enovis Corporation Gross Profit
Year Gross Profit Growth
2004 111.746.000
2005 123.125.000 9.24%
2006 136.798.000 10%
2007 175.591.000 22.09%
2008 217.187.000 19.15%
2009 185.787.000 -16.9%
2010 191.408.000 2.94%
2011 240.099.000 20.28%
2012 1.152.125.000 79.16%
2013 1.306.222.000 11.8%
2014 1.478.845.000 11.67%
2015 1.251.774.000 -18.14%
2016 1.145.651.000 -9.26%
2017 1.029.475.000 -11.28%
2018 1.132.839.000 9.12%
2019 1.401.056.000 19.14%
2020 1.288.105.000 -8.77%
2021 1.613.658.000 20.17%
2022 869.383.000 -85.61%
2023 971.864.000 10.54%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Enovis Corporation Net Profit
Year Net Profit Growth
2004 57.306.000
2005 12.247.000 -367.92%
2006 94.000 -12928.72%
2007 64.882.000 99.86%
2008 -571.000 11462.87%
2009 21.722.000 102.63%
2010 16.215.000 -33.96%
2011 4.555.000 -255.98%
2012 -64.402.000 107.07%
2013 178.628.000 136.05%
2014 392.098.000 54.44%
2015 167.739.000 -133.75%
2016 128.111.000 -30.93%
2017 151.090.000 15.21%
2018 140.196.000 -7.77%
2019 18.863.000 -643.23%
2020 64.082.000 70.56%
2021 98.693.000 35.07%
2022 -38.189.000 358.43%
2023 -11.520.000 -231.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Enovis Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 -2
2005 0 0%
2006 0 0%
2007 5 100%
2008 0 0%
2009 2 100%
2010 1 0%
2011 0 0%
2012 -2 100%
2013 5 150%
2014 9 55.56%
2015 4 -125%
2016 3 -33.33%
2017 4 0%
2018 3 0%
2019 0 0%
2020 1 100%
2021 2 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Enovis Corporation Free Cashflow
Year Free Cashflow Growth
2005 -14.835.000
2006 -27.591.000 46.23%
2007 60.812.000 145.37%
2008 -51.626.000 217.79%
2009 27.280.000 289.24%
2010 49.438.000 44.82%
2011 42.367.000 -16.69%
2012 80.713.000 47.51%
2013 290.687.000 72.23%
2014 304.415.000 4.51%
2015 233.936.000 -30.13%
2016 183.723.000 -27.33%
2017 150.005.000 -22.48%
2018 156.721.000 4.29%
2019 5.546.000 -2725.84%
2020 187.150.000 97.04%
2021 251.862.000 25.69%
2022 -161.311.000 256.13%
2023 3.982.000 4151%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Enovis Corporation Operating Cashflow
Year Operating Cashflow Growth
2005 -7.754.000
2006 -17.355.000 55.32%
2007 74.483.000 123.3%
2008 -31.513.000 336.36%
2009 38.286.000 182.31%
2010 61.965.000 38.21%
2011 57.153.000 -8.42%
2012 164.299.000 65.21%
2013 362.169.000 54.63%
2014 385.758.000 6.11%
2015 303.813.000 -26.97%
2016 246.974.000 -23.01%
2017 218.770.000 -12.89%
2018 226.367.000 3.36%
2019 130.948.000 -72.87%
2020 301.935.000 56.63%
2021 356.099.000 15.21%
2022 -55.861.000 737.47%
2023 31.013.000 280.12%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Enovis Corporation Capital Expenditure
Year Capital Expenditure Growth
2005 7.081.000
2006 10.236.000 30.82%
2007 13.671.000 25.13%
2008 20.113.000 32.03%
2009 11.006.000 -82.75%
2010 12.527.000 12.14%
2011 14.786.000 15.28%
2012 83.586.000 82.31%
2013 71.482.000 -16.93%
2014 81.343.000 12.12%
2015 69.877.000 -16.41%
2016 63.251.000 -10.48%
2017 68.765.000 8.02%
2018 69.646.000 1.26%
2019 125.402.000 44.46%
2020 114.785.000 -9.25%
2021 104.237.000 -10.12%
2022 105.450.000 1.15%
2023 27.031.000 -290.11%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Enovis Corporation Equity
Year Equity Growth
2004 98.090.000
2005 -7.579.000 1394.23%
2006 5.899.000 228.48%
2007 53.051.000 88.88%
2008 166.931.000 68.22%
2009 198.832.000 16.04%
2010 216.371.000 8.11%
2011 189.275.000 -14.32%
2012 1.912.352.000 90.1%
2013 2.513.889.000 23.93%
2014 3.146.826.000 20.11%
2015 3.069.975.000 -2.5%
2016 2.896.871.000 -5.98%
2017 3.500.415.000 17.24%
2018 3.476.946.000 -0.67%
2019 3.489.628.000 0.36%
2020 3.587.874.000 2.74%
2021 4.661.433.000 23.03%
2022 3.449.801.000 -35.12%
2023 3.441.732.000 -0.23%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Enovis Corporation Assets
Year Assets Growth
2004 707.881.000
2005 700.574.000 -1.04%
2006 797.226.000 12.12%
2007 896.540.000 11.08%
2008 913.076.000 1.81%
2009 1.003.131.000 8.98%
2010 1.022.077.000 1.85%
2011 1.088.543.000 6.11%
2012 6.129.727.000 82.24%
2013 6.582.853.000 6.88%
2014 7.245.098.000 9.14%
2015 6.732.919.000 -7.61%
2016 6.385.459.000 -5.44%
2017 6.721.648.000 5%
2018 6.603.872.000 -1.78%
2019 7.386.832.000 10.6%
2020 7.351.549.000 -0.48%
2021 8.515.345.000 13.67%
2022 4.273.248.000 -99.27%
2023 4.400.917.000 2.9%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Enovis Corporation Liabilities
Year Liabilities Growth
2004 609.791.000
2005 708.153.000 13.89%
2006 791.327.000 10.51%
2007 843.489.000 6.18%
2008 746.145.000 -13.05%
2009 804.299.000 7.23%
2010 805.706.000 0.17%
2011 899.268.000 10.4%
2012 3.973.441.000 77.37%
2013 3.841.738.000 -3.43%
2014 3.892.654.000 1.31%
2015 3.476.363.000 -11.97%
2016 3.292.115.000 -5.6%
2017 2.994.384.000 -9.94%
2018 3.126.926.000 4.24%
2019 3.897.204.000 19.76%
2020 3.763.675.000 -3.55%
2021 3.853.912.000 2.34%
2022 823.447.000 -368.02%
2023 959.185.000 14.15%

Enovis Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
30.45
Net Income per Share
-1.66
Price to Earning Ratio
-35.55x
Price To Sales Ratio
1.94x
POCF Ratio
105.14
PFCF Ratio
-32.07
Price to Book Ratio
0.94
EV to Sales
2.2
EV Over EBITDA
59.28
EV to Operating CashFlow
119.37
EV to FreeCashFlow
-36.38
Earnings Yield
-0.03
FreeCashFlow Yield
-0.03
Market Cap
3,22 Bil.
Enterprise Value
3,65 Bil.
Graham Number
48.53
Graham NetNet
-8.87

Income Statement Metrics

Net Income per Share
-1.66
Income Quality
-0.41
ROE
-0.03
Return On Assets
-0.01
Return On Capital Employed
-0.02
Net Income per EBT
0.49
EBT Per Ebit
1.08
Ebit per Revenue
-0.04
Effective Tax Rate
0.44

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.58
Operating Profit Margin
-0.04
Pretax Profit Margin
-0.04
Net Profit Margin
-0.02

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.56
Free CashFlow per Share
-1.84
Capex to Operating CashFlow
-4.28
Capex to Revenue
-0.08
Capex to Depreciation
-0.62
Return on Invested Capital
-0.02
Return on Tangible Assets
-0.07
Days Sales Outstanding
60.88
Days Payables Outstanding
64.95
Days of Inventory on Hand
244.59
Receivables Turnover
6
Payables Turnover
5.62
Inventory Turnover
1.49
Capex per Share
-2.4

Balance Sheet

Cash per Share
0,59
Book Value per Share
63,06
Tangible Book Value per Share
5.75
Shareholders Equity per Share
63.06
Interest Debt per Share
8.92
Debt to Equity
0.14
Debt to Assets
0.11
Net Debt to EBITDA
7.02
Current Ratio
2.4
Tangible Asset Value
0,31 Bil.
Net Current Asset Value
-0,10 Bil.
Invested Capital
0.14
Working Capital
0,50 Bil.
Intangibles to Total Assets
0.71
Average Receivables
0,29 Bil.
Average Payables
0,14 Bil.
Average Inventory
462405000
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Enovis Corporation Dividends
Year Dividends Growth

Enovis Corporation Profile

About Enovis Corporation

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

CEO
Mr. Matthew L. Trerotola
Employee
6.550
Address
2711 Centerville Road
Wilmington, 19808

Enovis Corporation Executives & BODs

Enovis Corporation Executives & BODs
# Name Age
1 Mr. Bradley J. Tandy
Senior Vice President & Chief Legal Officer
70
2 Mr. Matthew L. Trerotola
Chief Executive Officer & Chairman
70
3 Mr. Daniel A. Pryor
Executive Vice President of Strategy & Business Development
70
4 Derek Leckow
Vice President of Investor Relations
70
5 Mr. John Kleckner
Vice President, Controller & Chief Accounting Officer
70
6 Ms. Patricia A. Lang
Senior Vice President & Chief Human Resources Officer
70
7 Mr. Brady R. Shirley
President, Chief Operating Officer & Director
70
8 Mr. Phillip Benjamin Berry
Senior Vice President & Chief Financial Officer
70
9 Mr. Terry Ross
Group President Prevention & Recovery
70
10 Katie Sweet
Vice President of Corporate Communication
70

Enovis Corporation Competitors